| __timestamp | Ascendis Pharma A/S | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 19698000 | 8494000000 |
| Thursday, January 1, 2015 | 40528000 | 9046000000 |
| Friday, January 1, 2016 | 66022000 | 9095000000 |
| Sunday, January 1, 2017 | 99589000 | 10554000000 |
| Monday, January 1, 2018 | 140281000 | 10775000000 |
| Tuesday, January 1, 2019 | 191621000 | 11355000000 |
| Wednesday, January 1, 2020 | 260904000 | 12340000000 |
| Friday, January 1, 2021 | 295867000 | 14277000000 |
| Saturday, January 1, 2022 | 379624000 | 14135000000 |
| Sunday, January 1, 2023 | 413454000 | 15048000000 |
Cracking the code
In the world of pharmaceutical innovation, research and development (R&D) spending is a key indicator of a company's commitment to future growth. Over the past decade, Johnson & Johnson and Ascendis Pharma A/S have showcased contrasting trajectories in their R&D investments.
From 2014 to 2023, Johnson & Johnson consistently allocated a significant portion of its resources to R&D, with expenditures growing from approximately $8.5 billion to $15 billion. This represents a robust 76% increase, underscoring their dedication to maintaining a competitive edge in the healthcare sector.
In contrast, Ascendis Pharma A/S, a smaller player, demonstrated a remarkable growth rate in R&D spending, skyrocketing from $19.7 million in 2014 to $413 million in 2023. This exponential increase of over 2,000% highlights their aggressive pursuit of innovation and market expansion.
These figures not only reflect the companies' strategic priorities but also their potential impact on the future of healthcare.
Novo Nordisk A/S vs Ascendis Pharma A/S: Strategic Focus on R&D Spending
Johnson & Johnson vs Merck & Co., Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Johnson & Johnson vs Bristol-Myers Squibb Company
Research and Development Investment: Johnson & Johnson vs Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Johnson & Johnson and Celldex Therapeutics, Inc.
R&D Insights: How GSK plc and Ascendis Pharma A/S Allocate Funds
argenx SE or Ascendis Pharma A/S: Who Invests More in Innovation?
Research and Development Investment: Genmab A/S vs Ascendis Pharma A/S
Research and Development: Comparing Key Metrics for Ascendis Pharma A/S and TG Therapeutics, Inc.
R&D Insights: How Ascendis Pharma A/S and Xenon Pharmaceuticals Inc. Allocate Funds
Ascendis Pharma A/S vs ACADIA Pharmaceuticals Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Ascendis Pharma A/S and Agios Pharmaceuticals, Inc.